2 Blockbuster Gene Therapy Programs to Watch in 2019

There are so many companies trying doing something with gene therapy right now that trying to keep track of them all is a full-time job. If you're short on time but you still want to know which way the wind's about to blow for the overall gene therapy space, here's some good news: You can narrow your focus to two potential blockbusters.

We'll probably see new drug approvals for Zolgensma from Novartis (NYSE:NVS) and Lentiglobin from bluebird bio (NASDAQ:BLUE) before the end of the year, and both drugs are expected to generate more than $1 billion annually within several years.